David Siegel D, Oriol A, Rajnics P. et al. Updated results from ASPIRE and ENDEAVOR, randomised, open-label multicentre phase 3 studies of carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM). EHA 2017, abstract P333.
Europese goedkeuring pembrolizumab voor behandeling van recidief of refractair klassiek HL
mei 2017 | Lymfoom